Isomorphic Labs closed a $2.1 billion Series B, underlining how quickly Alphabet-linked assets are moving from model-building to clinical execution. The London-based AI biotech said Thrive Capital led the round, with Alphabet and Google’s GV also participating, joined by MGX, Temasek, CapitalG, and the U.K. government’s AI fund. The company plans to scale its unified drug design engine, IsoDDE, and accelerate its internal pipeline into the clinic. Isomorphic said the funding adds capacity to move faster from AI-discovered candidates toward preclinical and clinical programs. The announcement also reaffirmed Isomorphic’s deal track record with major pharma: both Eli Lilly and Novartis have tasked Isomorphic with using models including AlphaFold 3 for small-molecule discovery against undisclosed targets.